Severe Eosinophilic Asthma
Conditions
Interventions
Observation group:None
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patient has provided informed consent for study participation; 2. Patient is aged >=12 years at index date; 3. Patient has a confirmed clinical diagnosis of asthma as per physician’s assessment and is on medium- to high-dose ICS; 4. Patient on medium- to high-dose ICS initiates mepolizumab treatment for asthma as per the physician’s decision in routine practice; 5. Patient has relevant medical records available for >=12 months prior to enrollment;
Exclusion criteria
Exclusion criteria: 1. Patient has received mepolizumab more than 30 days prior to the enrollment; 2. Participation in an interventional clinical study 12 months prior to and at time of mepolizumab initiation; 3. Patient received biologics for any indication within 12 months prior to index date;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the change in rate of CSE in the 12- month period post mepolizumab initiation compared to the 12-month pre-exposure period for patients with asthma on medium- to highdose ICS in China.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in ACT score; | — |
Countries
China
Contacts
Public ContactZhang Min
Shanghai General Hospital
Outcome results
None listed